The Meningococcal Vaccines Market is projected to increase from USD 4.4 billion in 2026 to USD 5.9 billion by 2033, registering a CAGR of 4.5%. After reaching USD 4.1 billion in 2025, the Meningococcal Vaccines Market is entering a period in which growth opportunities vary considerably across vaccine brands, serogroups, age groups, and geographies.

Rather than following one uniform trajectory, the market combines established revenue contributors with emerging growth areas. These differences offer a clearer view of how the industry may evolve through 2033.

Four Market Shifts Worth Watching

1. Established vaccine categories continue to dominate.

Bivalent vaccines accounted for 80.3% of the market, making them the leading vaccine type. Menveo held a 29.6% share among brands, while serotype Y represented 32.9% of the serotype segment. These figures underline the importance of established categories in current market performance.

2. Faster growth is emerging in selected segments.

Nimenrix is projected to record a CAGR of 11.3%, while serogroup B vaccines are expected to grow at 5.8%. The infant segment is forecast to expand at 5.7%. Each of these categories is projected to grow faster than the overall market, although their starting positions differ.

3. Demand varies by patient group and sales channel.

Children and adults aged two years and older accounted for 63.2% of the market. The private channel represented 64.9% of revenue, demonstrating its substantial contribution to current distribution.

4. Regional leadership is changing in pace, not necessarily in size.

North America held 55.2% of market revenue in 2025, with the United States representing the largest country market. Asia Pacific, however, is projected to register the fastest regional growth, at a CAGR of 7.4%.

Download a free sample report or claim your copy of this full market intelligence report

Product Developments Are Adding New Dimensions

Market competition is not limited to existing vaccine brands. Combination vaccines and updates to product indications and presentations are also shaping the landscape.

Penbraya and Penmenvy are examples of combination vaccines within the market. Recent developments cited in the source information include GSK's Penmenvy approval in February 2025, an expanded infant indication for MenQuadfi in May 2025, and European Commission approval of Menveo's liquid, single-vial presentation in November 2024.

These milestones illustrate the continuing evolution of vaccine portfolios as manufacturers introduce products, expand indications, and modify presentations.

Regional Outlook: Two Different Positions

North America remains the market's leading revenue contributor, supported by its 55.2% share in 2025. Its current position contrasts with Asia Pacific's growth outlook.

With a projected CAGR of 7.4%, Asia Pacific is expected to expand faster than the overall market during the forecast period. This makes the region an important part of the future growth picture, even as North America maintains its leading position by revenue.

Key Companies

The competitive landscape includes major pharmaceutical manufacturers involved in the meningococcal vaccines industry:

• GlaxoSmithKline
• Pfizer
• Sanofi
• Merck & Co.
• Novartis

Explore the full list of profiled companies operating in this market with recent strategic initiatives

These companies operate within a market where established products remain important while product approvals and portfolio developments continue to shape competition.

The Road to 2033

The Meningococcal Vaccines Market is forecast to reach USD 5.9 billion by 2033, reflecting continued expansion. Its next phase will be defined by differences between market leaders and faster-growing categories.

Bivalent vaccines remain prominent by share, while Nimenrix has a stronger projected growth rate among the cited brands. Meanwhile, the infant segment and serogroup B vaccines offer additional growth areas, and Asia Pacific is expected to outpace the overall market. Together, these trends provide a differentiated picture of the industry's outlook.

Explore Our Research & Intelligence Solutions

Prism AI: Ask. Analyze. Get Cited Market Insights. – Explore Now

U.S. Healthcare Facility Intelligence: Make Better Decisions with Comprehensive Data – Explore the Platform